These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27758767)

  • 1. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.
    Griffin JH; Mosnier LO; Fernández JA; Zlokovic BV
    Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2143-2151. PubMed ID: 27758767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated protein C promotes neuroprotection: mechanisms and translation to the clinic.
    Griffin JH; Fernández JA; Lyden PD; Zlokovic BV
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S62-4. PubMed ID: 27207428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated protein C, protease activated receptor 1, and neuroprotection.
    Griffin JH; Zlokovic BV; Mosnier LO
    Blood; 2018 Jul; 132(2):159-169. PubMed ID: 29866816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.
    Wang Y; Zhao Z; Chow N; Ali T; Griffin JH; Zlokovic BV
    Brain Res; 2013 Apr; 1507():97-104. PubMed ID: 23438513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoprotective-selective activated protein C therapy for ischaemic stroke.
    Mosnier LO; Zlokovic BV; Griffin JH
    Thromb Haemost; 2014 Nov; 112(5):883-92. PubMed ID: 25230930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury.
    Gleeson EM; Dichiara MG; Salicio A; Quinn LM; Drakeford C; Russell SE; Walsh PT; Orbe J; Hermida J; Smith OP; O'Donnell JS; Montes R; Preston RJ
    Blood; 2015 Aug; 126(7):915-9. PubMed ID: 26084674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.
    Wang Y; Thiyagarajan M; Chow N; Singh I; Guo H; Davis TP; Zlokovic BV
    Stroke; 2009 May; 40(5):1864-9. PubMed ID: 19057019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.
    Wang Y; Sinha RK; Mosnier LO; Griffin JH; Zlokovic BV
    Blood Cells Mol Dis; 2013 Aug; 51(2):104-8. PubMed ID: 23541526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytoprotective protein C pathway.
    Mosnier LO; Zlokovic BV; Griffin JH
    Blood; 2007 Apr; 109(8):3161-72. PubMed ID: 17110453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An orthosteric/allosteric bivalent peptide agonist comprising covalently linked protease-activated receptor-derived peptides mimics in vitro and in vivo activities of activated protein C.
    Healy LD; Fernández JA; Aiolfi R; Mosnier LO; Griffin JH
    J Thromb Haemost; 2024 Jul; 22(7):2039-2051. PubMed ID: 38670314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity.
    Guo H; Wang Y; Singh I; Liu D; Fernández JA; Griffin JH; Chow N; Zlokovic BV
    J Neurochem; 2009 Apr; 109(1):116-24. PubMed ID: 19166505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.
    Wang Y; Zhao Z; Chow N; Rajput PS; Griffin JH; Lyden PD; Zlokovic BV
    Stroke; 2013 Dec; 44(12):3529-36. PubMed ID: 24159062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated protein C: biased for translation.
    Griffin JH; Zlokovic BV; Mosnier LO
    Blood; 2015 May; 125(19):2898-907. PubMed ID: 25824691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity.
    Guo H; Singh I; Wang Y; Deane R; Barrett T; Fernández JA; Chow N; Griffin JH; Zlokovic BV
    Eur J Neurosci; 2009 Mar; 29(6):1119-30. PubMed ID: 19302148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.
    Shibata M; Kumar SR; Amar A; Fernandez JA; Hofman F; Griffin JH; Zlokovic BV
    Circulation; 2001 Apr; 103(13):1799-805. PubMed ID: 11282913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1.
    Thiyagarajan M; Fernández JA; Lane SM; Griffin JH; Zlokovic BV
    J Neurosci; 2008 Nov; 28(48):12788-97. PubMed ID: 19036971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotection and vasculoprotection using genetically targeted protease-ligands.
    Rajput PS; Lamb JA; Fernández JÁ; Bai J; Pereira BR; Lei IF; Leung J; Griffin JH; Lyden PD
    Brain Res; 2019 Jul; 1715():13-20. PubMed ID: 30880117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C.
    Huuskonen MT; Wang Y; Nikolakopoulou AM; Montagne A; Dai Z; Lazic D; Sagare AP; Zhao Z; Fernandez JA; Griffin JH; Zlokovic BV
    J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34846535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
    Lyden P; Pryor KE; Coffey CS; Cudkowicz M; Conwit R; Jadhav A; Sawyer RN; Claassen J; Adeoye O; Song S; Hannon P; Rost NS; Hinduja A; Torbey M; Lee JM; Benesch C; Rippee M; Rymer M; Froehler MT; Clarke Haley E; Johnson M; Yankey J; Magee K; Qidwai J; Levy H; Mark Haacke E; Fawaz M; Davis TP; Toga AW; Griffin JH; Zlokovic BV;
    Ann Neurol; 2019 Jan; 85(1):125-136. PubMed ID: 30450637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells.
    Bae JS; Yang L; Manithody C; Rezaie AR
    Blood; 2007 Dec; 110(12):3909-16. PubMed ID: 17823308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.